Not Signed In -
Linezolid Oral Suspension |
Zyvox Suspension |
Clinical Trial: Time To Efficacy and Onset Of Action Of Linezolid
This study is no longer recruiting patients.
|
Purpose
To assess the onset of action of linezolid
| Condition | Intervention | Phase |
|---|---|---|
| Gram-Positive Bacterial Infections Skin and Connective Tissue Diseases | Drug: linezolid | Phase IV |
MedlinePlus related topics: Bacterial Infections
Study Type: Interventional
Study Design: Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study
Official Title: Time To Efficacy and Onset Of Action Of Linezolid In Skin and Soft Tissue Infections
Further Study Details:
Primary Outcomes: Time to defervescence
Secondary Outcomes: Reduction of CRP levels; Reduction of leucocyte count
Expected Total Enrollment: 120
Secondary Outcomes: Reduction of CRP levels; Reduction of leucocyte count
Expected Total Enrollment: 120
Study start: January 2003
Eligibility
Ages Eligible for Study: 18 Years and above, Genders Eligible for Study: Both
Criteria
Inclusion Criteria:
- suspected grampositive infection
- fever > 38 C
Exclusion Criteria:
- Infections to be treated successfully by surgical procedures
Location Information
Study chairs or principal investigators
Pfizer CT.gov Call Center, Study Director, Pfizer
More Information
Study ID Numbers: OXAA-0026-162
Last Updated: September 6, 2005
Record first received: September 2, 2005
ClinicalTrials.gov Identifier: NCT00147511
Health Authority: Germany: Federal Institute for Drugs and Medicinal Devices
ClinicalTrials.gov processed this record on 2005-09-13
Last Updated: September 6, 2005
Record first received: September 2, 2005
ClinicalTrials.gov Identifier: NCT00147511
Health Authority: Germany: Federal Institute for Drugs and Medicinal Devices
ClinicalTrials.gov processed this record on 2005-09-13
Resources
- Linezolid Oral Suspension (Drug Digest)
- Zyvox Suspension (Drug Digest)
email this page
print this page
bookmark this page
feedback on this page
